Form 4: Hims & Hers Health Chief Legal Officer Boughton Soleil Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Boughton Soleil, Chief Legal Officer of Hims & Hers Health, exercised stock options and sold shares of Class A Common Stock on January 21, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On January 21, 2025, Boughton Soleil, the Chief Legal Officer of Hims & Hers Health, Inc., executed stock options to acquire 50,000 shares of Class A Common Stock at an exercise price of $5.01 per share.
- Simultaneously, Soleil sold 50,000 shares at $30 per share and 4,153 shares at $28.68 per share.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 28, 2024.
- Following these transactions, Soleil directly owns 165,650 shares of Class A Common Stock and 644,154 stock options.
Sentiment
Score: 6
Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. The sales could be seen as slightly negative, but the existence of the 10b5-1 plan mitigates concern.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, although the 10b5-1 plan mitigates this concern.
Industry Context
Insider trading activity is closely monitored in the healthcare and pharmaceutical industries. Form 4 filings provide transparency into the transactions of company insiders, allowing investors to assess management's confidence in the company's prospects.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, including competitors in the telehealth space such as Teladoc Health and Amwell.
- The use of Rule 10b5-1 trading plans is a common strategy among executives to manage their stock holdings while avoiding accusations of insider trading, aligning with practices seen at similar companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholder sentiment, but the pre-planned nature of the sales should minimize any negative perception.
Key Dates
| Date | Description |
|---|---|
| 2022-03-24 | Initial vesting date for stock options (1/48th of options). |
| 2024-08-28 | Date of adoption of Rule 10b5-1 trading plan. |
| 2025-01-21 | Date of stock option exercise and stock sales. |
| 2032-02-23 | Expiration date of stock options. |
Keywords
Form 4, insider trading, stock options, Hims & Hers Health, Boughton Soleil, Rule 10b5-1, stock sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.